Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for D. Western Therapeutics Institute Inc. (4576:JPX), powered by AI.
D. Western Therapeutics Institute Inc. is currently trading at ¥70. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for D. Western Therapeutics Institute Inc. on Alpha Lenz.
D. Western Therapeutics Institute Inc.'s P/E ratio is -5.3.
“D. Western Therapeutics Institute Inc. trades at a P/E of -5.3 (undervalued) with modest ROE of -58.3%.”
Ask for details →D. Western Therapeutics Institute Inc. is a biopharmaceutical company involved in the research, development, and commercialization of therapeutic products. With a focus on innovative drug discovery, the institute works on creating compounds that address unmet medical needs. The company's portfolio includes candidates targeting various ocular diseases and conditions, catering to a niche yet crucial sector within the healthcare industry. By leveraging scientific expertise and cutting-edge technology, D. Western Therapeutics Institute aims to enhance treatment outcomes and improve patient quality of life. The company's role in the financial market is significant, as it contributes to advancements in pharmaceuticals and potentially offers new products that can transform existing treatment paradigms. Through partnerships, collaboration with research institutes, and investment in biotechnology, the company exemplifies the integration of scientific discovery and practical application in the dynamic field of biopharmaceutical innovation.
“D. Western Therapeutics Institute Inc. trades at a P/E of -5.3 (undervalued) with modest ROE of -58.3%.”
Ask for details →D. Western Therapeutics Institute Inc. (ticker: 4576) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 21 employees. Market cap is $3.4B.
The current price is 70 with a P/E ratio of -5.31x and P/B of 2.34x.
ROE is -58.28% and operating margin is -159.92%. Annual revenue is $388M.